title: Outcomes and management strategies in pregnancies with early onset oligohydramnios.
abstract: OBJECTIVE
  To evaluate the outcomes and management options in pregnancies with early onset oligohydramnios.
  
  
  METHODS
  The file datas of all pregnancies diagnosed as oligohydramnios or anhydramnios before 27 gestational weeks between January 2006 and September 2013 were evaluated retrospectively. The underlying pathology and associated anomalies, karyotype analysis, the outcome of the pregnancy (either termination or labour), and gestational week at the time of diagnosis were analyzed.
  
  
  RESULTS
  A total of 54 pregnancies were evaluated; mean gestational week at the time of the diagnosis was 19.8 ± 4.6. Mean maternal age was 27.28 ± 6.03. Thirty-seven pregnancies were anhydramniotic, 13 fetuses had associated anomalies, five of them had multicyctic dysplastic kidney, five had bilateral renal agenesis, one had hypoplastic right heart syndrome, one had clubfoot, and one had ventricular septal defect and cleft palate. Karyotyping was normal regarding the fetuses with structural anomalies. Nineteen patients had premature preterm rupture of membranes and 39 patients had termination of pregnancy.
  
  
  CONCLUSIONS
  The prognosis of early onset oligohydramnios is poor. Main determinant is gestational week at the time of the diagnosis.
authors.forename: B Artunc
authors.initials: BA
authors.lastname: Ulkumen
authors.forename: H G
authors.initials: HG
authors.lastname: Pala
authors.forename: Y Bulbul
authors.initials: YB
authors.lastname: Baytur
authors.forename: F M
authors.initials: FM
authors.lastname: Koyuncu
mesh_terms: D000015:Abnormalities, Multiple / Q000453:epidemiology*; D000028:Abortion, Induced; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002821:Chorioamnionitis / Q000517:prevention & control; D015331:Cohort Studies; D000013:Congenital Abnormalities / Q000453:epidemiology*; D019468:Disease Management; D005260:Female; D005322:Premature Rupture of Fetal Membranes / Q000628:therapy*; D005333:Fetus / Q000002:abnormalities*; D005865:Gestational Age; D006330:Heart Defects, Congenital / Q000453:epidemiology*; D006801:Humans; D007231:Infant, Newborn; D007668:Kidney / Q000002:abnormalities*; D007674:Kidney Diseases / Q000151:congenital* / Q000453:epidemiology; D008423:Maternal Age; D021782:Multicystic Dysplastic Kidney / Q000453:epidemiology*; D016104:Oligohydramnios / Q000453:epidemiology* / Q000209:etiology / Q000628:therapy; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011262:Pregnancy Trimester, Second; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents